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The work with the Nordic consensus report on asthma management started some years ago. The Nordic countries
have common socioeconomic conditions. We acknowledge the international as well as other European guidelines
providing valuable recommendations. Nevertheless, we felt the need to combine the common Nordic experiences in
order to have a local statement of asthma and asthma care, based upon Nordic clinical science and tradition. The
work has been rewarding and we acknowledge many valuable contributions from paediatricians, allergologists and
lung physicians in all Nordic countries. The response has so far been positive and we feel that the present material
reflects the main opinion of Nordic physicians taking care of asthma patients of all ages. However, the asthma and
allergy research field is rapidly developing. Thus, this document should merely be regarded as a time-limited
contribution to the continuing scientific discussion of this fascinating field.
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Asthma is a common disease, which aects all age groups.
Four to 10% of the population in the western world suers
from asthma.
It is still a matter of dispute whether asthma prevalence
really has increased, or if the increase in prevalence
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disease. The increase is probably real, and objective
measurements such as bronchial hyper-responsiveness to
methacholine and exercise tests, have confirmed an
increased prevalence over time. Many studies speak in
favour of a real prevalence increase, especially in children
and young adults, and the number of patients seeking
medical help because of asthma has increased. In Scandi-
navian countries the mortality among young children (54–
5 years) has decreased, probably due to improved acute
treatment and monitoring, as well as improved regular
treatment.
Alarming periods of sharply increasing asthma mortality
have been described in some countries: in the sixties in
England and Wales and more recently in New Zealand.
The direct and indirect expenses caused by asthma are
considerable and increasing. Asthma, as it manifests itself
in the community, is a major healthcare problem. The
disease not only demands community action in treatment
and care but, also, preventive measures in order to avoid
further increase.
Although the basic pathophysiological mechanisms
manifesting ultimately as asthma symptoms take place in
the airway structures of the lungs, asthma is character-
istically a disease with a strong relationship to environmental
and living conditions. The classical example is worsening
asthma caused by allergens and pollutants. Asthma
symptoms are also precipitated by various environmental
and physical factors, and respiratory virus infections are
major triggers of asthma episodes. In the Nordic countries
asthma symptoms caused by cold weather are common and
many environmental factors play a key role in the
prevention and management of asthma symptoms.
However, air pollution in a broad sense does not explain
the increased asthma prevalence. Several studies have# 2000 HARCOURT PUBLISHERS LTD
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allergy in Eastern European countries and in developing
countries, despite a high degree of air pollution. Therefore,
other factors such as microbial defence, sedentary lifestyle,
nutritional status and diet together with other living
conditions need to be addressed.
The capabilities of modern asthma management, includ-
ing preventive measures and early intervention with anti-
inflammatory agents, give a better outlook for asthma
suerers. However, asthmatics still have restrictions in daily
life such as disturbed night sleep, avoidance of physical and
social activities, and loss of school and work days. As a
consequence, various national asthma programmes and
guidelines have been published during the last few years.
Poor understanding of asthma among healthcare profes-
sionals, as well as among patients, is one reason for sub-
optimal asthma treatment results. The failure to identify
asthma symptoms, over-reliance on bronchodilators, re-
luctance to use inhaled steroids, insucient environmental
actions and the lack of objective follow-up and appropriate
treatment during asthma exacerbations are the problems
commonly seen in asthma care. Furthermore, failure to use
inhalation devices and bad treatment compliance are often
seen among asthmatics. Supervised asthma self-care pro-
grammes have been developed to overcome these common
problems. Education on dierent levels is needed before
modern asthma treatment can benefit the general asthma
population.
The Nordic countries share many similarities in their
social, cultural and economical status, and also in their
healthcare systems. Therefore it was decided to set up a
Nordic Asthma Consensus Group, with the task of
preparing common guidelines and suggestions for the
Nordic countries to meet the increasing challenges of
asthma.
Although this paper is intended mainly for physicians
and other healthcare professionals, it is hoped that many
important stakeholders such as administrators, environ-
mentalists, politicians involved in healthcare and health
educators will find the information useful. Wide national
co-operation, not forgetting public opinion, is needed to
alleviate the suering caused by asthma.
Successful asthma management is a combination of good
knowledge among professionals and the asthmatic patient.
Asthma care needs good facilities, which are useful
investments today to make savings for tomorrow.
Definition, diagnosis and early
intervention
DEFINITION
Asthma is a chronic airway disease characterized by
episodes of wheezing, cough and dyspnoea. It is associated
with inflammation of the intrapulmonary airways, which is
the main cause of bronchoconstriction. Several inflamma-
tory cells, the eosinophil being one of the most important,
and several cellular mediators are involved in the pathogen-
esis. The airways show increased responsiveness reactingwith smooth muscle constriction and inflammation to a
variety of stimuli. The airway obstruction may vary
spontaneously or can be reversed at least partly by
treatment.
PREVALENCE
The prevalence of current asthma in adults is between 2 and
5% in Nordic countries, the highest figures being reported
in northern parts of Sweden (1,2). The prevalence among
Nordic school children is about 5–10%, with the cumula-
tive incidence another 50% higher (3), implying a doubling
of asthma prevalence in 20 years time (4,5). This
evolutional pattern seems similar to observations in other
countries (6,7,8).
MORBIDITY AND MORTALITY
Despite the increased asthma incidence, a decrease in total
days of hospital treatment for asthma in children above 2–3
years of age, as well as in adults, has been noted during the
last decade (9,10,11). This mainly reflects the changes in
therapeutic approach that has occurred during this time
period in active anti-inflammatory treatment, largely in the
form of widespread introduction of use of inhaled steroids
for children with moderately severe asthma. This is
discussed in more detail in the Health economy section.
Mortality has remained unchanged or has decreased in
children. In Finland a decrease in mortality in relation to
the number of individuals suering from asthma has been
observed during the last 15 years (11).
ALLERGIC SENSITIZATION
Allergic sensitization is the production of specific Ig-E
antibodies to an allergen, not necessarily causing symp-
toms. The term ‘allergy’ means the presence of both specific
Ig-E and concordant symptoms, after exposure to the
relevant allergen. Allergic sensitization is more common in
children with asthma than in an adult population of
asthmatics. At least 70–80% of school children with asthma
are sensitized towards one or more common allergens (12),
whereas after the age of 40 years, less than 50% of the
population demonstrate the presence of specific Ig-E.
The frequency of respiratory allergy in the age group from
7–16 years has increased considerably during recent decades
(13). The ability to become sensitized depends upon genetic
factors and environmental exposure. Our genetic back-
ground has not changed and twin studies support the idea
that environmental influences are the major contributors to
the present situation (14,15).
Increased exposure to environmental allergens such as
animal danders, house dust mites and occupational
sensitizers may have taken place. However, allergen
exposure has always existed and sensitization has not only
increased to indoor allergens, but also to outdoor allergens
such as grass and birch pollen. These observations imply an
eect of some adjuvant factors which facilitate sensitiza-
tion. Examples of such adjuvant factors are tobacco-smoke,
1(Highest PEF7Lowest PEF)6100/Highest PEF
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viral infections. Children of smoking parents have a
substantially increased incidence of respiratory allergy, as
well as increased frequency of upper airway symptoms and
infections (16). Children spending their days in nurseries
have a considerably higher number of viral respiratory tract
infections, which also aggravates symptoms of respiratory
allergy. Other contributing factors that have been proposed
are general changes in the many aspects of life style
associated with urbanization, industrialization, viral and
bacterial infections and diet.
The increase in asthma prevalence represents a multi-
factorial problem threatening our society. New ideas are
urgently needed to avoid this health problem escalating
further.
Early detection of asthma and early intervention is
important. Early intervention does not only mean pharma-
cological treatment. It is important to identify the environ-
mental exposures. For example, in many cases of
occupational asthma, the duration of symptoms caused
by work-related agents is directly associated with long-term
prognosis of the disease (17).
When obstructive lung disorder is suspected, measure-
ment of lung function is as important as the measurement
of blood pressure in patients with hypertension. Any doctor
taking care of children and adults with symptoms in the
airways should have a peak flow instrument on his desk.
Cheap and reliable spirometry equipment is also available.
It is highly recommended that forced vital capacity (FVC)
and forced expiratory volume in 1 sec (FEV1) are recorded
early in the course of the disease, and that spirometry is
performed at least annually in order to detect a decline in
lung function over time.
TESTING OF REVERSIBILITY
If obstruction is suspected, a reversibility test should be
performed. Peak expiratory volume (PEF) or FEV1 are
recorded before and after bronchodilator treatment. In pre-
school children, tidal flow volume loops may be used (18).
After 400 g of inhaled salbutamol a maximal, or close to
maximal, bronchodilator response is usually achieved
within 5–10 min. Especially in middle aged and elderly
patients, 2-agonist treatment may be combined with
ipratropium bromide. The onset of bronchodilatation
following ipratropium bromide is slower and it is recom-
mendable to wait 25–30 min before a second spirometry is
performed. In children not able to inhale from a powder
inhaler or pressurized metered dose inhaler (pMDI) with a
spacer, a nebulized solution of salbutamol 0.05 mg kg71
may be used.
An improvement from baseline of PEF415% (or
460 l min71) or preferably FEVI412% (or 4200 ml)
means a clinically relevant reversible airway obstruction. In
doubtful cases, with insucient response, a spirometry after
doubling the dose should be performed. When using tidal
flow volume loops, a response larger then two SD of the
intra-subject baseline variation may be interpreted as a
positive response.In non-responsive patients with persistent obstruction, an
oral course of steroids can be instituted (e.g. prednisolone
20–40 mg daily for 2 weeks) and the reversibility test re-
peated. The increase of FEVI4500ml or PEF4100 lmin
71
from baseline strongly suggest an asthma diagnosis in
adults (19).
A normal lung function at the time of investigation does
not by any means exclude asthma. If the history indicates
recurrent obstruction, the patient should be instructed to
measure PEF at home for a period of 1–2 weeks. PEF
should be recorded the morning and evening before and
after 2-agonist inhalation, as well as on demand (e.g. when
symptoms occur). This is especially important when
environmentally induced obstruction is suspected.
A diurnal variability1, with or without bronchodilator,
415% (and more than 60 l) during 2 or more out of 7 days
indicates asthma.
BRONCHIAL OBSTRUCTION RELATED TO
RESPIRATORY TRACT INFECTION IN
ADULTS
Many patients report their asthma as having started at the
time of a respiratory tract viral infection. Some viral
infections may have a pathophysiological role in the
development of asthma and cause exacerbation of already
existing asthma (see below).
The presence of airway obstruction in relation to
respiratory tract infection is common and should not
immediately be regarded as presence of asthma. However,
most latent asthmatics, and those at risk of developing
asthma, will present with obstruction related to respiratory
tract infection. Consequently, a liberal use of spirometry
and reversibility testing in patients with infection related
airway symptoms is warranted.
Initiation of anti-inflammatory treatment in all patients
with airway obstruction induced by infection could lead to
unnecessary treatment. A short course of bronchodilator
treatment (2 and/or ipratropium bromide), sometimes
combined with oral acetylcysteine or antitussives, often
provides sucient relief for the vast majority of patients.
However, it is important to re-evaluate the situation 1–2
months after the acute episode, in order to pick up those
patients who have not fully recovered. In those cases, need
for anti-inflammatory treatment (i.e. corticosteroids)
should be evaluated.
WHEEZING IN INFANTS
Obstruction of the intrapulmonary airways in connection
with respiratory infections is a common paediatric problem.
It can be estimated that at least 15% of children have
recurrent symptoms of airway obstruction at some point
during infancy or at pre-school age. The clinical picture is
characterized by wheezing, rhonchi, tachypnoea and chest
retractions. The triggering factors are virus infection, most
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virus and rhino viruses (20,21,22). During the winter
season, RSV can be demonstrated in half of the infants
and toddlers hospitalized for such airway obstruction (23).
At pre-school age, about 50% of children hospitalized
because of ‘wheezing bronchitis’ when below 2 years of age
have been found to have asthma (23). At school-age this
figure decreases to about 25–30% (20,24,25). Factors
correlating to persistence of asthma are atopy, that is other
atopic diseases than asthma, usually atopic dermatitis or
food allergy, and intense airway obstructive disease (23).
On the other hand, total-IgE at birth or at the time of the
first hospitalization is a poor predictor for development of
asthma during infancy, or persisting asthma, respectively
(23,26). Several follow-up studies have failed to demon-
strate significant dierences in long-term prognosis related
to the initial specific virus agent demonstrated at the first
hospitalization (20,23,25,27), although it is possible that
very early RSV bronchiolitis may induce a process leading
to asthma (28).
The implication of wheezing in connection to virus
infections and asthma triggered by infections is debated.
Recurrent symptoms, or symptoms in a child above the age
of 2 years, suggests asthma. The diagnosis asthma can be
strongly considered in the following circumstances:
1. From the third attack of airway obstruction during the
last year is current asthma.
2. One attack of asthmatic symptoms occurring after the
age of 2 years.
3. Irrespective of age in an attack in children with eczema,
food allergy or other allergy.
4. If the child does not become free of symptoms when
infection has ceased, or has persistent symptoms for
more than a month.
Use of the asthma diagnosis from the third attack of
airway obstruction is widely accepted. Empirically asth-
matic symptoms appearing after the age of 2 years usually
reflect hyper-reactive airways, which motivates use of the
diagnosis asthma earlier than from the third episode of
asthmatic symptoms. Similarly, when asthmatic symptoms
with wheeze and rhonchi appear in an infant with other
atopic symptoms, odds are high that asthmatic symptoms
will recur at least up to school-age. This does not contradict
that there are mild as well as severe forms of the disease,
and that symptoms may disappear with age. The advan-
tages of early asthma diagnosis according to the above
criteria are to promote an active approach in terms of
advice to parents, prophylaxis and pharmacotherapy.
‘ALL THAT WHEEZES IS NOT ASTHMA’—
DIFFERENTIAL DIAGNOSTIC PROBLEMS
IN THE INFANT AND YOUNG CHILD
Respiratory infections
Airway symptoms such as stridor, chronic cough, or
wheezing can be initiated by many dierent infectiousagents like RSV, parainfluenza and rhino viruses, a least in
children. Bordetella pertussis, Mycoplasma, Chlamydia
pneumoniae and Tuberculosis should be considered in
patients with chronic cough who are not responding to
asthma treatment.
Cystic fibrosis
Cystic fibrosis (CF) in infants can start with symptoms of
airway obstruction. Suspicion should arise when the clinical
picture does not really fit. Children with CF often have
recurrent pneumonias and poor weight gain. The correct
diagnosis is obtained from the sweat test. In CF there is an
elevated sweat chloride level 460 mmol l71. Genetic
analysis supports the diagnosis.
Vascular anomalies
Usually this is a so-called vascular ring, which is often
constituted by a double aortic arch. In the embryo, there is
originally a ventral and a dorsal aorta. The ventral aorta
should disappear during the fetal period. If this does not
occur, the ventral aorta will compress the trachea and
oesophagus like a snare. A symptom is more or less
continuous stridor, audible in inspiration as well as
expiration. A barium swallow will give the correct
diagnosis. The vascular ring surrounding the oesophagus
and trachea is visualized as a notch in the oesophagus.
Treatment is surgical division of the vascular ring.
Laryngo-tracheomalacia
Congenital stridor, especially inspiratory stridor, starts in
the neonatal period. The symptoms are aggravated during
airway infections and when the child gets upset. The stridor
disappears during the first year of life as cartilage in the
trachea and larynx becomes firmer.
Cardiac diseases
Cardiac diseases with increased pulmonary blood flow may
have symptoms similar to asthma.
Chronic lung disease of the newborn—broncho-
pulmonary dysplasia
This lung disease with fibrosis can aect preterm children
treated with artificial ventilation with high pressures and
oxygen concentrations. The children usually have hyper-
reactive airways and asthma-like symptoms with deteriora-
tion during respiratory infections. These children usually
benefit from the pharmacotherapy given to children with
asthma.
TABLE 1. Costs for asthma in Sweden 1993 [in millions
Swedish crowns from Persson et al. 1994 (34)]
Children Adults
Direct health costs
Drugs 972 2269
Outpatient treatment 1536 3585
Hospitalization 529 3436
Indirect costs, lost production
Sick leave 1831 4546
Supplementary disability pension 77 15190
Early death 191 1584
Total 5136 3061
NORDIC CONCENSUS REPORT ON ASTHMA MANAGEMENT 303Corpus alienum
When suspicion of the diagnosis arises, the parents often
start to remember a preceding episode when the child
coughed violently while eating peanuts, a carrot, an orange
segment or something similar. Pneumonia which recurs at
the same location, or changes on chest X-ray which remain
following treatment, should raise suspicion.
Tumours
Tumours, such as a lymphoma, leading to bronchial
obstruction can produce symptoms similar to those of a
corpus alienum.
Hilar lymph gland enlargement
Enlarged lymph nodes in tuberculosis can produce symp-
toms which can be misinterpreted as asthma.
Operated oesophageal atresia
These children often have asthmatic symptoms with
deterioration in connection with viral infections.
Chronic lung disease due to immunodeficiency
Immunodeficiencies, such as deficiency of IgG or IgA, are
often associated with respiratory tract infections and the
potential development of bronchiectasis, as well as with
allergic diseases.
Ciliary abnormalities and impaired mucociliary
clearance
Ciliary defects can be misinterpreted as asthma. The clinical
picture resembles cystic fibrosis with pneumonias which do
not fully resolve. Electron microscopy of cilia obtained via
biopsy from nasal or tracheal mucosa can give the
diagnosis.
Pulmonary sequestration
This is characterized by non-functioning embryonic lung
tissue with a blood supply from the systemic circulation.
The tissue usually does not communicate with the
functioning lung tissue. The condition is rare but should
be considered in cases of recurrent or longstanding
pneumonias with the same localization. Treatment consists
of extirpation after the diagnosis has been established.
Lobar emphysema
Abnormal lobar distension can produce respiratory distress
in an otherwise normal new born or infant. The lobarhyperaeration involves partial bronchial obstruction or
intrinsic alveolar disease. Progressive respiratory distress
from birth to 6 months of age, especially in the first month,
parallels the degree of emphysema. Cough, wheezing,
dyspnoea, tachypnoea, tachycardia, stridor and intermit-
tent cyanosis are aggravated with feeding. Excisional
therapy should be done when the diagnosis is accompanied
by symptoms.
Vocal cord dysfunction
This condition is more likely to occur in adolescence,
especially in teenage girls, than in childhood. The symp-
toms usually appear in connection to physical exercise and
appear as stridorous breathing. The symptoms are often
perceived as quite dramatic, both for patients and
bystanders. The symptoms disappear without treatment
when the patient relaxes. Quite naturally the response to
anti-asthmatic treatment is poor and there is a risk attached
to unnecessary medication. Fiberoptic visualization of the
larynx region during exercise can give the diagnosis.
Inspiratory and expiratory flow–volume spirometry during
attacks is also helpful.
Health economy
Asthma is a common chronic disease which means large
costs for the healthcare system (29,30,31,32). The still rising
numbers of individuals suering from asthma emphasizes
the economical burden implied by the disease. Total annual
costs of asthma in the U.S.A. has been calculated to $US
6206 million (33). For 1993 the society’s annual costs for
asthma in Sweden was calculated to SEK 3061 million ($US
398 million) for adults and SEK 514 million ($US 67
million) for children, amounting to a total of SEK 3575
million ($US 464 million) (34).
Two economically important consequences of persistent
asthma are hospitalizations and lost production due to
illness and retirement, and these may be reduced by
improving treatment and patient education (11). In Den-
mark, the costs in 1995 for a ‘well treated patient’ were
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year. The costs for a patient with severe disease were DKK
171 489 and with mild disease 3180 per year. The total
annual costs were estimated to be DKK 9.6 billion for an
asthmatic population of 212 000.
In Finland it was estimated that 20% of those patients
receiving reimbursement for drug costs—caused by regular
medication—had severe disease while 60% had mild
disease. The severely ill patients however cause 60–70%
of the costs. To reduce the costs the patients with severe
asthma should be treated more eectively, but in the long
run preventing escalation of asthma to become persistent in
the patients with mild to moderate disease could be even
more cost saving (11,35).
Early diagnosis and appropriate medication of asthma
reduces overall morbidity from the disease. Furthermore,
optimal care and successful implementation of asthma
management plans are valuable, not only for the well-being
of the individual asthmatic, but for the profound eect on
health economy. Such asthma management strategy in-
volves avoidance of asthma triggers (e.g. passive smoking,
house dust mites, indoor pets) and optimal drug therapy,
which probably will not only reduce morbidity but also
facilitate long-term preservation of lung function (36). In
addition, early intervention with anti-inflammatory treat-
ment most likely alters the natural course of the disease
(37,38,39). Action plans for acute exacerbations have
reduced asthma morbidity, and asthma education for
children and adults has demonstrated cost savings in
addition to health benefits (40).
During the last 20 years, asthma prevalence in school
children in Sweden has doubled to 5–8% (4,41). The same
trend has been demonstrated in Norway, which currently
has prevalence figures approaching 10% (3), Denmark and
Finland. Other European countries show a similar pattern.
In some countries, such as the U.S.A., such a trend has led
to increased hospitalization. However, during the last
decade there has been a major change in the approach to
asthma treatment, with a shift of emphasis from bronch-
odilators towards continuous anti-inflammatory treatment,
mainly inhaled steroids. It seems that the net eects have
been profound in terms of reduced exacerbation rates,
hospital admission rates and number of hospital days for
asthma (10). This can be illustrated with figures from
Gothenburg, Sweden’s second largest town with half a
million inhabitants. During the last decade there was a
drastic decrease in the total number of hospital days for
acute asthma in children. In the age group 2–18 years
hospitalization gradually has decreased to a third (9). Both
the admission rate and the number of individuals admitted
to hospital has decreased. Thus, children less often need
hospital treatment, and when they do they need shorter
hospital stays. There were no corresponding major changes
in emergency unit policies in the treatment of acute asthma
during this time period which could account for the
observed changes. Although increased eorts in education
of parents/patients may have contributed favourably, the
major reason for this remarkable decrease in hospitaliza-
tion is most likely treatment with inhaled steroids, in
children with asthma who need more than a few doses of2-agonist per week (42,37). This strongly supports the
cost-eectiveness of the anti-inflammatory therapeutic
approach.
More widespread use of preventive, anti-inflammatory
medication, and a reduction in reliance on bronchodilators,
are probably the single most eective measure that can be
taken in order to reduce the costs implied by asthma.
In 1981, the Finnish Social Insurance Institution
recorded 49 259 asthma patients who where entitled to
special reimbursement for their drug costs. In 1996 the
figures had increased by three-fold, to 159 105 patients
(population 5.1 million). Nevertheless, days in hospital per
asthmatic population in 1996 were only one quarter of that
in 1981, and mortality due to asthma showed a similar
trend. In England, Wales and New Zealand the asthma
mortality has also dropped since the late 1980s, in spite of
an increasing prevalence of asthma (43). However, in the
United States and Japan, asthma mortality is low but still
increasing. The reason for these dierences are obscure.
Although several factors have probably contributed to
the positive trend in Finland and many other countries —
the disease may even have become milder — early and
better treatment of asthma deserves much credit for the
favourable development. The consumption of short acting
2-agonists has been stable in Finland for several years,
while the use of inhaled corticosteroids continues to
increase. In 1996 the ratio of prescriptions of prophylactic
anti-asthmatic medication to 2-agonists exceeded 1.0 in
Finland, the first Nordic country where this occurred (44).
Education
Education on all levels is crucial for successful results when
dealing with the problems caused by asthma.
An educated patient with increased knowledge is the key
to better compliance, better well-being and better disease
control.
SPREADING GENERAL ASTHMA
KNOWLEDGE
The general public should have some basic knowledge of
asthma. This may facilitate the everyday life of asthmatics.
Increased general awareness of environmental factors
known to adversely aect asthma may lead to diminished
exposure to irritants (e.g. tobacco smoke) and allergens in
the home, at work, in school and at day-care centres as well
as in public areas. Better general knowledge of asthma is
likely to benefit individuals suering from asthma, because
of better understanding and support from family friends
and others. There are still misconceptions of asthma in the
population. The harmful idea that asthma is psycho-
somatic is still prevalent. Good general awareness of
asthma also facilitates preventive measures and early
recognition of the disease. The implementation and
development of established community allergy clinics is
valuable.
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PROFESSIONALS
Sound information about asthma is important when it
comes to choice of a suitable profession for a young
asthmatic. It is also beneficial for the patients suering
from asthma that many non-medical professionals, includ-
ing architects, constructors, social workers and employ-
ment ocials, have a certain knowledge of the disease.
Since asthma is common among school children, teachers
should be educated and informed about the disease in order
to meet the need of the children with asthma. This includes
avoiding asthma trigger factors, helping the child with
medication when required and aiding the child in normal
social relations.
EDUCATION OF THE MEDICAL
COMMUNITY
1. The concepts of asthma have changed considerably and
this must be taken into account when planning basic
educational programs for medical students and nurses as
well as post-graduate education for physicians.
2. It must be stressed that the amount and quality of
education given should be in balance with the importance
and prevalence of this common disease. This is not the
fact today. The majority of asthma care today is provided
by GPs, and therefore special eorts should be directed to
improve primary care. Treatment of asthma is much more
than prescription of drugs and includes above all patient-
education. In order to implement patient education it is
important that not only physicians are involved but that
other health providers also take part. Specially trained
nurses used for asthma education is one possibility.
Experiences with asthma school have been rewarding.
Patient education is a continuous and demanding process
which should start when the asthma diagnosis is given andTABLE 2. Key points for education of patients in asthma care
. Patient education should begin at the time of diagnosis a
. It is essential that education be provided by all members o
the key educational messages and negotiate agreements wit
by all members of the healthcare team.
. Teach asthma self-management, tailoring the approach to
beliefs and practices.
. Teach and reinforce at every opportunity:
Basic facts about asthma;
Role of medication;
Skills: inhaler/spacer/holding chamber use, self-monito
Environmental control measures;
When and how to take rescue actions.
. Jointly develop treatment goals.
. Encourage an active partnership, provide all patients with
exacerbations. Action plans are especially important for
history of severe exacerbations. Provide appropriate patie
. Encourage adherence by promoting open communicatio
emphasizing goals and outcomes; and encouraging familycontinued indefinitely. The responsibility for successful
patient education lies primarily with the physician but must
be seen as a general challenge for all healthcare profes-
sionals. The family members of an asthmatic are also an
important target group for asthma education.
PATIENT EDUCATION
Education and well organized, structured care on all levels
are essential for successful results when dealing with the
problems caused by asthma.
Recent treatment guidelines (45,46) have emphasized the
importance of patient education in the self-management in
asthma care. It should begin at the time of diagnosis and be
integrated into every step of care. Eective consultations
have an essential role in educating patients and provide the
opportunity to determine individual levels of disability.
HOW TO IMPROVE COMMUNICATION
WITH THE PATIENTS
Research emphasizes a need for health professionals to
show a greater understanding of individual patient con-
cerns and their health beliefs, and how these influence
compliance with the medical treatment and advice (47). In
order to achieve this, health professionals should identify
and develop their communication style to improve their
own eectiveness during consultations with patients.
Strategies have been identified to improve communica-
tion with patients, enhance information exchange and focus
medical visits on the patients personal goals (48,49). These
strategies may dier somewhat from culture to culture, but
comprise good general guidelines:
They are that the professionals:
1. are attentive to the patient (signalled by cues such as
using eye contact, sitting rather than standing when
communicating with the patient, moving closer to thend be integrated into every step of clinical asthma care.
f the healthcare team. The principal clinician should introduce
h patients. These messages should be reinforced and expanded
the needs of each patient. Maintain a sensitivity to cultural
ring;
a written daily self-management plan and an action plan for
patients with moderate-to-severe asthma and patients with a
nts with a daily asthma diary.
n; individualizing, reviewing and adjusting plans as needed;
involvement.
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discussion);
2. elicit the patient’s underlying concerns about the
condition;
3. construct reassuring messages that alleviate fears
(reducing fear as a distraction enables the patient to
focus on what the physician is saying);
4. address immediate concerns expressed by the family
(again enabling patients to refocus their attention
toward the information being provided);
5. engage the patient in interactive conversation through
use of open-ended questions, simple language, analo-
gies to teach important concepts (an interactive
dialogue provides richer information);
6. tailor the management plan by eliciting and addressing
potential problems in the timing, dosage, or side eects
of the medications prescribed;
7. use appropriate non-verbal encouragement (e.g. a pat
on the shoulder, nodding in agreement) and verbal
praise when the patient reports using correct disease
management strategies;
8. elicit the patient’s immediate objective related to
control of the disease and reaching agreement with
the family on a short-term goal (that is, a short-term
objective important to the patient, which both provider
and patient will strive to reach);
9. evaluate the long-term treatment outcome;
10. help the patients to use the diary information, or
guidelines to handle potential disease problems in
advance.
KEY CONSTITUENTS OF ASTHMA PATIENT
EDUCATION
Patient education can be divided into a basic knowledge
and specific skills. Careful consideration is required in
planning educational intervention that enables patients to
acquire skills and not simply information about asthma.TABLE 3. Key educational messages for patients
Check o or document that the following key messages have b
Basic facts about asthma
The contrast between asthmatic and normal airways
What happens to the airways in an asthma attack
Roles of medications
How medications work
Long-term control; medications that prevent symptoms
Quick relief; short-acting bronchodilator relaxes muscle
Stress the importance of long-term-control medications an
Skills
Inhaler use (patient demonstrates)
Spacer/holding chamber used
Symptom monitoring, peak flow monitoring and recogniz
Environmental control measures
Identifying and avoiding environmental precipitants or ex
When and how to take rescue actions
Responding to changes in asthma severity
(daily self-management plan and action plan)BASIC KNOWLEDGE OF ASTHMA
This part of patient education includes a knowledge of
basic lung anatomy and physiology, the nature of asthma
disease, the causes of asthma, the asthma trigger factors
and their avoidance as well as basic pharmacology of
asthma drugs and basic principles of asthma treatment. The
information must be simple and easily adopted.
SPECIFIC SKILLS
The goal for this part of patient education is to facilitate
and encourage an asthmatic to live a life as normal as
possible despite his disease. The patient should be provided
with skills to perform a guided self-management pro-
gramme. This includes the ability to make home measure-
ment of lung function (PEF and FEV1) and to interpret
the results. The patient should also be well trained to
recognize symptoms of asthma deterioration. In many cases
symptoms appear before lung function deteriorates. In
some cases the opposite is shown, with obvious changes in
lung function with few or no symptoms recognized. Thus
the individual pattern should be identified. This enables
early recognition of the deterioration in asthma. The
appropriate use of inhaled devices is fundamental for
successful asthma management. The action plan of what to
do, when asthma is worsening, should be given both written
and verbally.
GUIDED SELF-MANAGEMENT
The goal of the guided self-management of asthma is to
prevent asthma exacerbations with early interventions
made by the patient and to maximize the benefits of the
treatment. Another aim is to make the patient feel
responsible and confident so that he/she feels in control
of the disease.een covered:
, often by reducing inflammation
s around airways
d not to expect quick relief from them
ing early signs of deterioration
posures
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step plan for self-management (Table 4).
Action plans and self-monitoring should be tailored to
patient’s skill levels and life-style and may be based on
either peak flow or symptoms. Recent research on guided
self-management of asthma suggests that it is most suitable
for patients suering from severe or moderate asthma.
However, patients who are unsuitable for self-management
education or do not want to take the full responsibility for
their condition can still achieve benefit from a structured
program of regular medical review (51,52).
PATIENT FOCUSED CONSULTATION
Consultations may have either a health professional or
patient centred approach. During a health professional
centred consultation the patient is asked a series of
questions in order to identify problems and is prescribed
treatment or management considered appropriate by the
health professional.
While this approach may be preferred by some patients,
it can be associated with a number of drawbacks. Over-
directed interviewing and frequent interruptions by the
health professionals may mean that the consultation is not
focused on the patients personal goals and needs, and
important emotional or psychological problems may not be
elicited. Patients with expectations left unfulfilled following
consultation are less likely to comply with treatment,
particularly if they feel it has been prescribed without
sucient attention being paid to their own concerns.
In contrast, in a patient centred approach, the patient
takes the lead and directs the consultation. The patient is
given the opportunity to discuss their own personal
concerns and those aspects which cause the most dicul-
ties. The objective is for the patient to understand the
problems and reach agreement or consensus by negotiation
with the health professional on the management of their
condition.
The patient centred approach may often be more
appropriate for asthma care allowing improved self-
management and enabling the patients to acquire the
knowledge, conviction and ability to make informed
choices and enhance their quality of life.
EDUCATION IN A STEPWISE MANNER
All patients with asthma should receive appropriate
information. It is important not to overwhelm the newTABLE 4. Asthma self-management (50)
Step 1: Know how severe your asthma is
Step 2: Achieve your best lung function
Step 3: Avoid asthma triggers
Step 4: Stay at your best
Step 5: Have an action plan
Step 6: Educate and review regularlypatient with too much information. It is better to provide
small amounts of information at more frequent intervals.
Table 5 gives recommendations for the context of both
initial visits and follow-up for asthma patients. They oer
suggestions on how to structure each consultation including
assessment questions, specific information and examples of
educational interventions in order to provide the patients
with appropriate skills to manage the condition.
DIFFERENT SETTINGS FOR PATIENT
EDUCATION AND SELF-MANAGEMENT
A large number of studies have been carried out in order to
provide evidence that one setting is more eective than
another for patient education. Overall, for adults and
children, there is no clear evidence that one setting is better
than another. Some studies have shown benefits in one
setting where others have not. Many of the studies have
evaluated educational outcomes rather than morbidity. The
population and the severity of the disease diers from
secondary care to primary care.
It is both possible and eective to educate patients in
many kinds of settings such as primary care, emergency
departments, inpatient wards, clinics, community organiza-
tions and pharmacies and, last but not least, at schools.
Each setting oers specific advantages and limitations
that should be viewed as shaping the educaional goals that
can be attained. Therefore the best setting is probably the
one where the patient actually attends, wants to learn most
and is most receptive to behaviour alteration.
THE VALUE OF DIFFERENT KINDS OF
EDUCATIONAL MATERIALS
Patient education can be accomplished through several
dierent mediums. Pamphlets, books, videos, audiocas-
settes, asthma educational courses, support groups, televi-
sion programs, the Internet, video games and direct contact
with the healthcare professional are all methods that can be
utilized in order to spread information. Nevertheless
research has demonstrated these approaches to be dier-
entially eective.
It does appear that the most preferred and eective
methods for controlling asthma are those which emphasize
personal interaction and opportunities for personalized
advice (53). Thus, it has been suggested that information
should first be relayed to the patient verbally with direct
opportunity for feedback, followed by reinforcement
through various techniques. In order to give patients
appropriate information it is important to realize that a
patient’s sense of control appears to depend as much on
information about life implications of the disease process as
on information about diagnosis and treatment (54).
There is a high patient demand for written information
that gives clear advice on what action to take to supplement
what they are told in health consultations. Another
important issue to consider is the appropriate readability
level. Studies give evidence that both high and low
education groups understand, remember and prefer simply
TABLE 5. Delivery of asthma education by clinicians during patient care visits
Assessment questions Information Skills
Information for initial visit
Focus on: Teach in simple language Teach or review and demonstrate:
Expectations of visit Inhaler and spacer/holding
Goals of treatment What is asthma? chamber use.
Medications A chronic lung disease.
The airways are very sensitive.
Check performance.
Quality of life They become inflamed and
narrow. Breathing becomes
dicult.
Self-monitoring skills that are tied
to an action plan:
‘What worries you most
about your asthma’
Asthma treatments. Two
types of medicines are needed:
Recognize intensity and
frequency of asthma symptoms.
What do you want to
accomplish at this visit?
Long-term control: Medications
that prevent symptoms,
often by reducing inflammation.
Review the signs of
deterioration and the need
to reevaluate therapy:
‘What do you want to be
able to do that you can’t
Quick relief: short-acting bronchodilator
relaxes muscles around airways.
Waking at night with
asthma.
do now because of your asthma?’ Increased medications use
Decreased activity tolerance.
‘What do you except
from treatment?’
Bring all medications to every
appointment.
Use of a simple written self-
management plan and action plan.
‘What medicines have you tried?’
‘What other questions do you
have for me today?’
When to seek medical advice.
Provide appropriate telephone number.
Recommendations for first follow-up visit (2 to 4 weeks or sooner as needed)
Focus on:
Expectations of visit
Goals of treatment
Medications
Quality of life
Teach in simple language.
Use of two types of medications.
Remind patient to bring all
medications and the peak
flow meter to every
appointment for review.
Teach or review and
demonstrate.
Use of a daily self-management
plan.
Review and adjust as
needed.
Ask relevant questions from
previous visit and also ask:
Self-evaluation of progress
in asthma control using
symptoms and peak flow
as a guide.
Use of an action plan.
Review and adjust as needed.
What medications are
you taking?
Peak flow monitoring and daily
diary recording.
‘How and when are you
taking them?’
‘What problems have you
had using your medications?’
‘Please, show me how
you use your inhaled
medications?’
Correct inhaler and
spacer/holding chamber
technique.
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NORDIC CONCENSUS REPORT ON ASTHMA MANAGEMENT 309written material better than the more sophisticated. Studies
also show that there is no significant dierence between
videos and written materials in patient perception of
healthiness and retention of information (54).
In order to assure consistency and continuity it is
important that health professionals from both the second-
ary and the primary care team develop strategies for shared
care, both in regard to diagnosis, treatment and education.
According to this a patient-kept record may be a simple and
eective tool.
Non-pharmacological treatment
THE ENVIRONMENT IS OF MAJOR
IMPORTANCE
The airways constitute one of the bodies largest exposure
areas to the environment. The airways have an elaborate
defence system including cough, surface lining with mucous
production and an active immunological system. In asthma
stimuli result in an exaggerated response with inflammation
of the mucosa, cough and altered mucus. Both sensitization
to airborne allergens and asthmatic inflammation, as well as
the occurrence of symptoms and attacks, are strongly
related to environmental exposure. Asthma is often
associated with inflammation of nasal mucosa and the
conjunctiva. This emphasizes the importance of exposure to
airborne triggers.
The environmental agents or triggers causing asthma
symptoms have been divided into inducers, agents which
cause allergic inflammation (environmental allergens and
sensitizers), and inciters which mainly elicits symptoms in
hyper-reactive subjects (i.e. cold air, exercise, airway
irritants etc.).
PRIMARY PREVENTION
Avoidance of environmental tobacco smoke (ETS)
It has been demonstrated that smoking during pregnancy
reduces lung function measured in the neonatal period (55).
Furthermore, parental smoking during early childhood
increases the risk of developing asthma (25). Avoidance of
tobacco smoke exposure during infancy is probably the
most important preventive measure that can be undertaken.
Moreover, it is extremely cost-eective. In adults, smoking
has been shown to increase sensitization (56).
Allergy avoidance
Avoidance of allergens and sensitizers has been attempted
to prevent the development of asthmatic disease in the first
place. Such actions have been proved to be valuable in the
work environment to prevent occupational asthma (57). In
contrast, there are conflicting data regarding the ecacy of
allergy avoidance in the home environment, aimed atpreventing later development of allergic sensitization or
development of asthma. Prospective studies have shown
that the risk of sensitization to indoor allergens increases in
proportion to specific allergen exposure (e.g. cat and house
dust mites (14)). Others have found that exposure to animal
allergens during the first year of life, prevents atopic rhinitis
and allergic asthma (58). Moreover, one study has shown
that farmer’s children are less often sensitized to aero
allergens then other children in rural Switzerland (59).
However, very early exposure to aero allergens may well be
a risk factor. The existence of a particularly vulnerable
period around the age of 3 months has been hypothesized.
It has been demonstrated that children born in the pollen
season are more prone to development of allergic sensitiza-
tion toward pollen allergens, especially in seasons with high
pollen counts (60). These conflicting data point towards the
existence of important unknown confounding factors
making strategies for primary prevention based upon
scientific evidence dicult.
SECONDARY PREVENTION
In already established asthma, action should be taken to
avoid exposure to specific allergens and known triggers. A
prolonged exposure to an allergen in a sensitized person is
associated with a high risk of persistent and worsening
disease (61,62). It is also known that repeated exposure to
low levels allergen doses, which for the patient are
unnoticeable, can lead to asthma development (63). On
the other hand, early intervention and removal from
exposure give good possibilities of remission (64). Protec-
tion can be divided into source control and exposure
control. An example of source control is exclusion of
indoor animal dust exposure, and examples of exposure
control are an increase in house ventilation and use of
mattress covers for avoidance of house dust mite exposure
(65). In all cases action should be taken to detect specific
allergens. However, the general improvement of the
environment and reduction of environmental irritants
should be regarded as the major task. It is important to
enforce research to identify harmful agents.
SPECIAL CONSIDERATION
House dust mite
Presence of house dust mites (HDM) is highly dependent on
indoor humidity. Because of dry winters HDM allergy is of
less importance in the northern part of Scandinavia. In
contrast, in the southern part, HDM represents an
increasing indoor allergen problem. Presumed explanations
have been mild winters in combination with insulated
houses and little natural ventilation.
Good ventilation, to reduce the indoor air humidity
(5458 relative humidity) in winter months, is important.
This may, however, not always be possible. Mite allergen
tight bed covers encapsulate mites and reduce exposure
from the bed.
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chemicals to combat mites, are of unknown value and these
may themselves worsen asthma.
Allergy towards pets
Cat and dog allergens are ubiquitous and impossible to
fully avoid. It is known that after removal of the animal
and careful cleaning of the dwelling, allergens in large
quantities may persist for months. The half life of these
allergens are not known.
This motivates the introduction of an ‘allergy clean’
certificate for a home. It should be possible for those with
severe allergy to choose furniture and dwellings which are
guaranteed to be free from animal allergens and that the
construction of the dwelling makes it possible to decrease
the risk of mite replication.
Air cleaners
Many air cleaners are presently on the market which are
proposed to be eective in reducing the amount of allergens
in the air. However, most of the systems are small with
insucient capacity to make any impact on the air quality,
even in very small rooms. Many patients ask for commu-
nity funding for such equipment. At this time there is no
evidence to support the use of this equipment among
allergic individuals.
Vacuum cleaners
Conventional vacuum cleaners disperse allergen particles in
large amounts. Vacuum cleaners with ‘allergen filters’ or
central vacuum systems can avoid acute challenge. Many
devices exist on the market and there is no direct
correlation between ecacy and price. Consequently it is
wise to consult a local specialist before investing in such
equipment.
Air ionizers
Air ionizers have no proven eect and cannot presently be
recommended.
Specific allergen vaccination
Specific allergen vaccination has been used since the
beginning of this century. The eect on seasonal allergic
rhinoconjunctivitis is well documented (66,67,68). A recent
study indicates a possible preventive eect upon asthma
development by specific allergen vaccination in pollen
allergic children with allergic rhinoconjunctivitis (69). In
allergic asthma, usually somewhat higher maintenance
doses are needed to achieve an appreciable eect (70). This
leads to longer treatment periods and a high risk of side
eects, especially in those individuals with decreased lungfunction. Specific allergen vaccination is not recommended
in individuals with FEV1570% and in those with unstable
asthma.
A clinically significant eect on asthma has been
documented for allergen vaccination with pollens, cat,
dog and house dust mite allergen. With the standardized
allergens present today, the risk with allergen vaccination is
low when following recommended procedures (71). Initia-
tion of specific allergen vaccination should only be carried
out by trained physicians.
Monitoring—follow-up
ACTIVE QUESTIONING, EXAMINATION
AND MANAGEMENT
It is important to detect under-treatment with active
questioning for asthmatic symptoms in specific situations,
for example physical exercise or early morning symptoms.
Furthermore, the physical examination should be active,
and include listening to lung sounds during forced
expiration. Sometimes rhonchi and wheezing become
audible in that situation.
Careful clinical observation is even more important for
the small child. It is important to register the child’s
behaviour during daily activity. Observation of the child
during play and physical activity gives the trained physician
a good idea of the present condition of the child.
Management plans are important in all cases of asthma.
For children they should be made in co-operation with the
parents in order to prevent the child from being hampered
in his/her daily physical activities.
The monitoring and management of asthma should take
into account the long and short perspective. In the short
run it is important to achieve sucient disease control in
order to help the patient live a normal or ‘close to normal’
life. In the longer perspective it is important to avoid the
development of chronicity and also try to avoid the
development of irreversible changes of lung function.
OBJECTIVE MEASUREMENTS OF DISEASE
CONTROL
A normal lung function should be achieved throughout the
day. During the initial phase of the disease the subject
should be instructed to record PEF morning and evening,
as well as on demand. This should be done in order to
establish the diagnosis and to assess the disease severity.
Moreover, the patient learns during this phase to relate
symptoms to disease severity. Moreover, in the initial
registration period, it is often wise to let the patient measure
PEF before and after 2-agonist inhalation. A consistent
diurnal variation2 after inhalation of 2-agonist of more
than 10%, indicates insucient disease control. Home
monitoring of PEF for a week before a visit to the doctor,
preferably combined with a reversibility test when the
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increase in the patient’s PEF-value of more than 10% 15–
20 min after inhalation of 2-agonist suggests that the
patient has a bronchoconstriction and indicates less than
optimal treatment.
Early in the evaluation phase it is important to establish
the individual optimal PEF value, which later will serve as a
‘reference value’. The patient should know his/her optimal
‘normal’ PEF range and be taught how to act when the
PEF value falls below that interval. Children are usually
able to measure PEF from 5–6 years of age.
A spirometry should be done on a regular basis when the
patient comes to visit the doctor. Spirometry with flow–
volume loops provides additional information of peripheral
airway functions (MMEF25/75, FEF50). While a spirometry
is often normal when the patient sees the doctor later on
during the day, regular PEF registration detects the disease
variability and thus give a better view over the degree of
disease control. A spirometry, especially the post-bronch-
odilator value, if performed at regular intervals, may reveal
a tendency of long-term deterioration in lung function.
It should be mentioned that not all subjects benefit from
PEF registration and, especially in children, a low grade
relationship has been demonstrated between PEF-monitor-
ing and disease activity (72). Both children and parents
have diculties in correctly perceiving and assessing
degrees of airway obstruction (73). Thus the physician
should, after an initial evaluation phase, decide whether
useful information is obtained from continuous PEF
registration. In most situations it is sucient to only use
PEF measurements on demand when the disease situation
changes or asthma medication is changed, and during
asthma deteriorations.
BRONCHIAL HYPER-RESPONSIVENESS
(BHR)
Monitoring of bronchial hyper-responsiveness with metha-
choline (PD20) was found to be superior to conventional
assessment of severity by symptoms and lung function.
When BHR was included as a monitoring tool, superior
disease control was achieved, including better symptom
control, improved lung function, fewer exacerbations and
morphological evidence of decreased airway remodelling
(74).
INFLAMMATORY MARKERS
Clinical disease control is dependent on the control of the
underlying inflammation in the bronchial mucosa. Thus,
parameters that reflect the degree of underlying inflamma-
tion would be of importance. The measurement of blood
eosinophil count and serum concentration of eosinophil
cationic protein (ECP) have been proposed for follow-up of
asthmatic inflammation. Activated eosinophils play an
important role in the late asthmatic response and in the
asthmatic airway inflammation (75). ECP is a toxic protein
secreted by activated eosinophils (76). Correlation has been
demonstrated between the severity of asthma and ECPlevels in bronchoalveolar lavage (75,77). Measurement of
ECP may be of importance in certain clinical settings, such
as monitoring of eects of anti-inflammatory therapy, as
well as an indicator of under-treatment or poor drug
compliance (78,79). However, individual variation is large
and whether or not it may be valuable in all asthmatics,
needs to be evaluated. In the future, measurement of
eosinophil protein X (EPX) or eosinophil peroxidase (EPO)
may oer advantages (80). EPX can be measured in urine,
for obvious reasons an advantage in paediatric practice
(80). Urinary measurement of ECP is not possible.
Eosinophilic airway inflammation can be readily studied
from induced sputum, which has been shown to be similar
to lower respiratory secretions expectorated spontaneously
(81), and to give comparable results to more invasive
bronchoscopic methods (82). The presence of eosinophils in
sputum is a more sensitive marker of asthmatic airway
inflammation than the blood eosinophils or serum ECP
(83,84). In asthmatic children treated with inhaled budeso-
nide for 6 months, significant clinical improvement was
accompanied by a decrease in sputum ECP, whereas serum
ECP did not change (85).
ASTHMA SYMPTOMS CONTROL
A disturbed night’s sleep, due to asthma symptoms,
profoundly aects the performance during the day. Possible
restrictions in daily activities are important to detect. Is the
patient able to use public transport, visit a restaurant or go
to a movie? Is he/she able to perform physical exercise and,
importantly, is the asthma disease interfering with relation-
ships with family or friends.
The physician should identify factors and situations that
limit the patients possibility of living a normal social life.
Moreover, the physician should help the patient to identify
these situations and then assist in learning to manage them.
This may lead to adjustment of maintenance therapy and
constructions of as needed medication schedules to be used
in these situations. Some situations may even be avoided.
The important thing is that the patient has professional
guidance in learning how to manage these problems. It is
often a delicate balance between the acceptance/sacrifice
asked from the environment and what is being demanded
by the patient.
LONG-TERM FOLLOW-UP
The long-term goal should be to avoid persistence of the
disease and occurrence of irreversible airway damage (86).
A spirometry when the patient is in an optimal condition
should be achieved early in the course. Thereafter, it is
recommended that the patient should be followed with
spirometry regularly during the years. While daily PEF-
measurement is excellent for monitoring short-term asthma
control, a spirometry measuring lung volumes and FEV1,
preferably with a flow–volume curve, is recommended for
long-term follow-up. In early detected asthma, a provoca-
tion test for bronchial responsiveness (87) or an exercise test
is often valuable (88). Changes in the degree of bronchial
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information of the long-term disease control. This is
especially important in children where exercise control
reflects function in daily activities (89). However it should
be noted that in patients with long-standing disease, the
reactivity may not change much over time, despite adequate
anti-inflammatory therapy (90).
Pharmacological treatment strategies
basic considerations
DISEASE MANIFESTATIONS
Asthma should be considered as a heterogeneous disorder,
and as such needs to be individually characterized in order
to select the correct treatment strategy.
The dierent compartments of the respiratory tract may
influence the disease presentation and severity. Concomi-
tant rhinitis should be treated with the same accuracy as
asthma disease itself. A blocked nose forces the patient to
breathe more through the mouth, thereby exposing the
lower airways to unfiltered, unconditioned air.
Many patients with allergic rhinitis, without asthma
symptoms, are known to have concomitant bronchial
hyper-responsiveness. This hyper-responsiveness increases
during allergen season and some patients are only hyper-
reactive during the season. It has also been shown that
provocation with methacholine in the nose produces an
increased lower airway resistance in susceptible rhinitis
patients (91). If the hyper-responsiveness is associated with
lower airway symptoms, there is need for treatment. It is
not known whether treatment of asymptomatic hyper-
reactivity decreases the risk of later asthma development.
Asthma inflammation involves all parts of the lower
airways. The more severe the disease, the more involved is
the entire respiratory tract, including the peripheral air-
ways. Severely obstructed patients not only have airflow
limitations, they also develop complete occlusion of parts of
the peripheral airways, leading to a decreased forced vital
capacity (FVC) and increased residual volume (RV) with an
increased amount of unventilated areas.
This type of obstruction is usually not completely
reversed by acute bronchodilatation, and inhaled corticos-
teroids may likewise be insucient to reach all aected
airways. In such cases, a short course with systemic steroids
is warranted, as a complement to starting treatment with
inhaled corticosteroids.
DRUG DEPOSITION—COMPLIANCE
Both the peripheral and the central airways are important
in asthma pathophysiology.
The severity of asthma is associated with the degree of
airway inflammation. Inflammation does not only vary in
intensity, but also in distribution within the entire bronchial
system. Consequently, to achieve maximum control, it isimportant to also assure sucient drug deposition in the
peripheral airways.
The inhalation device should ideally deliver a dose with
heterogeneous particle distribution with a size range in
adults between 2 and 6 m, to reach all airways. In children
with smaller diameters of the airways, this ideal diameter is
probably lower.
Moreover, the inhalation flow should not be too high,
since it has been shown that the higher the flow the more of
the drug is likely to be delivered in the central airways.
Extremely slow inhalation flow (at 3 l min71) facilitates
peripheral deposition in normal, but also in obstructive,
inividuals (92).
The patient must, in addition to being motivated to take
the medication, have a proper inhalation technique
(technical compliance). Poor compliance is probably the
most common reason for insucient treatment response
and should always be considered before changing treatment
strategy. Therefore check of inhalation technique should be
routine in almost every asthma visit.
AGE — DISEASE DURATION
Anti-inflammatory treatment, preferably with inhaled
corticosteroids, is the treatment of choice in all asthma
patients with newly detected disease. Early intervention not
only improves asthma symptoms and lung function, but
also to a certain degree restores bronchial hyper-respon-
siveness, may normalize the airway structure and, in
children, ensures normal growth of lung function (93,94).
There are also indications, that early intervention in a
longer follow-up perspective, reduces the total amount of
steroids needed for control of the disease.
The addition of a long-acting 2-agonist or leukotriene
antagonist should be considered when optimal disease
control is not achieved with medium to high doses of
corticosteroids.
In contrast to patients with newly detected disease,
disease with a longer duration (usually more than 3 years) is
less likely to be fully controlled by inhaled corticosteroids
alone (95,37). In these patients, it may be adviseable to add
long acting 2-agonists or leukotriene antagonists earlier, if
they are already on a low to medium dose of corticosteroid
therapy.
TREATMENT STRATEGY
The philosophy of asthma treatment has profoundly
changed in recent years. At the moment the three widely
accepted principles of asthma therapy are: 1. anti-inflam-
matory management is introduced at an early stage of the
disease; 2. anti-inflammatory medication is supplemented
with bronchodilators; 3. physician-centred management is
replaced by patient-orientated management plans.
Approximately 60% of asthma patients are symptom-
free most of the time and have very mild or mild symptoms,
which may increase in certain situations (e.g. during
respiratory infections, irritant or allergen exposure). Ap-
proximately 20% of patients have moderate symptoms
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about 5%, have very severe symptoms with frequent life-
threatening exacerbations (96).
The same patient may have mild symptoms on one
occasion and extremely severe symptoms on another.
Asthma is a disease with marked fluctuation of activity,
which is caused by various trigger factors, or variation may
take place spontaneously. Symptomatic asthma should
always be treated pharmacologically, although other
prophylactic treatments play a central role.
In practice, the clinician deals with a newly diagnosed
patient, who has mainly been without long-term treatment
(early management of asthma), or a patient with a history
of asthma for some time, and who has already been using
drugs (chronic management of asthma).
EARLY MANAGEMENT OF ASTHMA
The initial symptoms of asthma — mucus production,
occasional cough and wheezing — are clinical markers of
the inflammatory reaction of the bronchial mucosa.
Measurable disturbances of lung function indicate that
the process has been going on for some time. This
emphasizes the importance of early detection of symptoms
and abnormalities of lung function. Early diagnosis and
treatment improve outcome of asthma and overall need for
medical help.
ANTI-INFLAMMATORY MEDICATION
When the diagnosis of asthma has been objectively
established and symptoms or signs of asthma are
present more than twice weekly, long-term treatment is
started with inhaled corticosteroid, which is the drug of
choice.
The anti-inflammatory treatment is introduced as first-
line treatment to gain control of the disease as fast as
possible. Initially, a quite large dose of inhaled steroid is
used, which is then step-wise reduced, according to the
clinical response, to the smallest dose able to control the
symptoms. The dosage is individually chosen with con-
sideration of disease activity, therapeutic benefits and side-
eects. Most of the steroid-treated patients become
symptom-free. However, it is not known how long steroid
treatment should be continued after the remission, or what
kind of dosage schedules should be recommended. If
symptoms are fully controlled we recommend the con-
tinuation of regular anti-inflammatory treatment, the dose
of which can vary, for 1–2 years after the diagnosis, before
intermittent use is tried. For anyone initiating treatment
with inhaled corticosteroids, it is their responsibility to
ensure that the treatment is eective and that subsequent
dose adjustment and titration takes place. In patients
who do not respond fully to inhaled corticosteroids or go
on developing a chronic persistent asthma, long-term
management with combination therapy is preferred
(described in more in detail the section ‘long-term manage-
ment’ below).In patients with severe obstruction and evidence of small
airway occlusion, a short course of systemic steroids is
recommended (see above).
If the initial symptoms are severe, treatment is started
with oral corticosteroids (prednisone, prednisolone, methyl-
prednisolone). For example, 20–40mg prednisolone is given
every morning for 10–14 days. For short courses of oral
steroids, there is no need to taper o the dosage. High-dose
inhaled steroid is introduced simultaneously. The treatment
is continued with the inhaled steroid.
The topically active corticosteroids used in Scandinavia
today are safe and eective in long-term clinical use in low
and moderate doses. In daily dosages above 1000 g in
adults and 400 g in children, an influence on biochemical
parameters appears. However, due to large individual
dierences in steroid sensitivity, these limits are not
absolute and stress the importance of individual assess-
ments. In children, a short-term eect on growth, even on
low steroid doses has been observed, although the long-
term relevance is not known (97). The disease itself is a
major stress causing metabolic changes, which normalize
when the bronchial inflammation is tackled by therapy but
long-term experience is lacking.
Leukotriene antagonists oer a new approach in asthma
treatment. Full dose response curves for clinical outcome
parameters, such as lung function, symptom control and
exacerbation rate, still need evaluation. The optimum dose
may dier considerably between individuals.
Several studies have shown significant protection against
various forms of challenge tests including exercise (98,99)
and most studies show an eect compared to placebo. More
comparisons with other established therapies, especially to
inhaled corticosteroids, are needed. Patients with concomitant
rhinitis and impaired smell, may benefit from these treat-
ments, especially those patients with known non-steroidal
anti-inflammatory drugs (NSAID) intolerance (100).
Leukotriene antagonists interfere with asthma pathogen-
esis in a way dierent from corticosteroids and 2-agonists.
The inability of corticosteroids to suppress leukotriene
production indicates that leukotriene antagonists may have
a complementary action to inhaled corticosteroids in the
control of asthma. Further knowledge is needed to establish
whether leukotriene antagonists may influence airway
remodelling and long-term outcome. Leukotriene antago-
nists has been found to have additional eects to inhaled
corticosteroids, and beneficial eects from leukotriene
antagonists as add-on therapy to inhaled steroids, indicates
that this may be advantageous (101,102).
Long-term studies are needed to evaluate whether
leukotriene antagonist treatment, as a single anti-inflam-
matory treatment, have impact on long-term lung function
and bronchial hyper-responsiveness.
CHROMONES
In some adults with mild symptoms, nedocromil or
cromoglycate may be symptomatically eective (whereas
the eect on the bronchial inflammation is weak). However,
there are no means to predict the ecacy of cromoglycate
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should be abandoned.
MONITORING THE NEED FOR ANTI-
INFLAMMATORY THERAPY
At present, in general practice, the need for therapy is
judged by clinical evaluation (symptom history, lung
auscultation) and lung function measurements (PEF and
spirometry). Measurement of lung volumes, bronchial
responsiveness and exercise tests can give additional
information. Biochemical markers of the inflammatory
process, indicating cell activity and measured in serum and
sputum (e.g. eosinophilic cationic protein, ECP), may be of
value (see monitoring, page 33).
Patients should as soon as possible be able to take
responsibility for continuous treatment and management of
the disease. This is done through a self-management plan based
upon recognition of asthma symptoms and self-monitoring of
lung function by method, such as PEF or FEV1.
STEROID RESISTANCE
The lack of clinical response to steroids does not exclude
the diagnosis. A genuine steroid resistance exists, and there
are subgroups in which the cellular response does not
follow the usual pattern. In these patients the eects of
steroids may be altered.
However, before a patient is regarded as steroid resistant,
factors like non-compliance, poor inhalation technique, strong
persistent trigger factors and allergens should be considered.
In addition, a re-evaluation of the diagnosis should be made.
BRONCHODILATORS; 2-AGONISTS,
ANTICHOLINERGICS AND
THEOPHYLLINES
Short-acting 2-agonists are used as rescue medication and
are essential drugs for acute or sub-acute symptoms.
Regular use is, however, not indicated in maintenance
treatment of newly detected asthma. They are used ‘as
needed’, which has two major advantages. Firstly, they help
to recognize optimum disease control, because the use is
minimal, when control has been achieved. Secondly,
increased use of 2-agonists is usually an early sign of
worsening asthma.
Long-acting 2-agonists are not usually employed in
newly detected asthma. Their use is indicated, if disease
control is not achieved with moderate doses of inhaled
corticosteroids, the patient needs short-acting 2-agonist
several times a day or has nocturnal symptoms (103).
Regular treatment with long-acting 2-agonists twice
daily has been shown to induce a certain degree of
tolerance. Usually the bronchodilator response is main-
tained, whereas the protective eect towards direct and
indirect stimuli is reduced. Tolerance develops rapidly
within a few days. However, the loss of protection is partial
and protection does not disappear or deteriorate furtherover time. In clinical studies, no convincing anti-inflamma-
tory eects have been described when patients have received
regular treatment [for review see (104)].
The addition of long-acting 2-agonists to a moderate
dose of inhaled corticosteroids improves lung function,
symptom control and reduces asthma exacerbations in
patients with chronic asthma (103,105).
Inhaled anticholinergics may be used instead of 2-
agonist in patients who are sensitive to side-eects (muscle
tremor, palpitation) of 2-agonists. The bronchodilation
eect of inhaled anticholinergics is caused by blocking of
the eerent parasympatic nerves on the post-ganglionic
level, thereby reducing the vagal tone in the airways (106).
Ipratropium bromide has proven to be a first line drug in
the treatment of patients with COPD (107). However, the
bronchodilation seen in asthma, especially in those of a
young age is modest and inferior to that seen with 2-
agonists (108,109). Ipratropium bromide has a slower onset
than 2-agonists and has no eect on the early or late
allergic reaction. Ipratropium bromide delivered by nebu-
lizer has synergistic eect to 2-agonist therapy in
asthmatics with acute exacerbation (110).
Theophylline has been considered as a bronchodilator
agent, but recently non-bronchodilator eects have been
detected. Examples of potential positive eects are in-
creased mucociliary clearance (119) improved diaphrag-
matic muscle function (111), stimulation of the respiratory
drive (112,113), and decreased vascular resistance in the
lungs (114). Theophylline has also been proposed to have
some anti-inflammatory potential (115,116), but the clinical
importance needs to be determined.
Theophylline has the disadvantage of a narrow ther-
apeutic index and a wide spectrum of side eects. The most
common toxic side eects are due to neurological and
cardiovascular actions with nausea and vomiting, seizures,
tachyarrythmias and muscle cramps. Another disadvantage
is the hazard of metabolism of other drugs with common
metabolic pathways in the liver (117). Important examples
are, Verapamil, Cimetidine, Disulphirame, Phenytoin and
several antibiotics as Erythromycin, Ciprophloxacine,
Rifampicine and Isoniazid. In addition theophylline meta-
bolism is influenced by diet and smoking.
Theophylline may be helpful in patients whose disease is
not fully controlled with moderate doses of inhaled
steroids, who use a short-acting 2-agonist several times a
day and have nocturnal symptoms (118). Theophylline may
be an alternative to long-acting 2-agonists, but the latter
seems more eective.
Despite the disadvantages, theophylline is still frequently
used in clinical practice. Recent data also demonstrates that
theophylline has some pharmacological properties support-
ing a continuous use of the drug in some defined clinical
settings (119).
ANTIBIOTICS, ANTITUSSIVES,
EXPECTORANTS
The bronchial inflammation is not usually caused by
microbes, and antibiotics are indicated only if signs of
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adults and children asthma often manifests and worsens in
association with a viral respiratory tract infection. Viral
infections may trigger inflammation leading to asthma and
are therefore not treatable with antibiotics. Asthmatic
airways excreting excess mucus are associated with cough.
When the asthmatic inflammatory reaction is treated,
antitussives and expectorants are not needed.
LONG-TERM MANAGEMENT OF ASTHMA
There are a wide variety of clinical stages in an asthmatic
population, for example a patient with 50 years of symptom
history and a patient who has wheezed for a week. The two
patients need totally dierent treatment strategies, but anti-
inflammatory medication is essential for both.FIG 1. Classification of disease severity is according to the glob
early phase of the disease, the primary goal should be to achie
underlying inflammation. This may have positive eects on the
Later in the phase, during step-down/tapering o, the primary
minimal risk for long-term side eects. Corticosteroids in med
recommended in early disease management, while in the chroni
leukotriene antagonist as add-on therapy to inhaled corticostero
medium dose of inhaled corticosteroids, it is important to cons
persistent environmental trigger factors or bad technical or me
done when optimal inflammatory control is dicult to achieveIt is essential to diagnose other diseases of the lungs
including concomitant irreversible airways obstruction.
There are patients who seem to have severe and chronic
asthma from the very beginning (usually non-allergic
asthma manifested in association with a respiratory
infection), as well as patients with mild disease for decades.
All asthma patients, who have had abnormal lung function
at some time of their disease, should be monitored and
oered special evaluation when needed.
Pharmacological treatment depends on the severity of
symptoms and functional abnormality. A patient who has
recovered from newly detected asthma, is free of symptoms
and has normal lung function does not necessarily need any
medication, while a patient with severe daily symptoms may
need oral and inhaled steroids, 2-agonists, and theophyl-
line. In very severe cases experimental treatments such as
cyclosporin or methotrexate may be tried in specialist
clinics.al initiative for asthma (GINA) guidelines (120). During the
ve rapid control of the clinical disease as well as over the
long-term prognosis and facilitate good patient compliance.
goal should be to maintain optimal disease control with
ium to high dose + short acting 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c phase, combination therapy with long-acting 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ids is preferred. When optimal control is not reached with a
ider other reasons for insucient response. This could be a
dical compliance. A steroid reversible test should always be
or questioned.
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first step always aiming to achieve good control of the
disease. Reduction of therapy, a step-down, is considered,
when the good result has been sustained for months.
Increase of therapy, a step-up, is indicated, when control
cannot be achieved with the current medication. This
usually means increase of the dose of inhaled steroid, giving
a burst of oral steroid and/or introduction of new drugs,
long-acting 2-agonists, leukotriene-antagonist, theophyl-
line, ipratropium etc. If asthma is not controlled by a daily
dose of inhaled steroid equivalent to 1 mg beclomethasone
diproprionate, other mechanisms should be considered.
Other therapies and referral to a specialist must be
considered.
The use of nebulized therapy for chronic use is seldom
necessary. Usually, for those with co-ordination problems,
excellent results are achieved by the use of powder
inhalators or pMDI and a volume spacer. Nebulized
therapy should be reserved for those with severe asthma
with frequent exacerbations insuciently controlled by
high dose inhaled steroids.
MANAGEMENT OF EXACERBATIONS
If the patient uses an inhaled steroid, the current dose is
immediately doubled during an exacerbation caused by
respiratory infection, allergen exposure or unidentified
reason. If doubling the dose of inhaled steroid does not
help in 24 h, a short course of oral steroid, for example 20–
40 mg prednisolone once daily, is used. Symptoms are
further controlled by the regular use of bronchodilators.
Under these circumstances temporary treatment with long-
acting 2-agonists should be considered. Tapering of the
oral steroid dose is usually not necessary when the course
does not exceed 2 weeks.
Despite the fact that nebulizers are no more eective than
ordinary pMDI or powder inhalers, they are frequently
used in some areas partly due to local traditions. Nebulizers
may be of use in some patients who have diculties with
other inhaled therapies.
It is essential to communicate time aspects and principles
of treatment to the patient. In the early stage of disease the
goal is to achieve rapid symptom control which takes 8
weeks with moderate or high dose corticosteroid. The step-
down is a slow process during the next year whereafter
intermittent therapy may be possible.
PHARMACOLOGICAL TREATMENT
STRATEGIES IN CHILDREN
The treatment strategy for children is basically the same as
for adults, with a few exceptions, as add-on therapy
strategies are less well documented. Respiratory allergy is
a much more common aetiology in children of 2 years and
older than in adults above 50 years of age. Environmental
control and allergy avoidance has a central role in asthma
management.
Moreover it is often possible to detect the disease in
young adults and children early in the course of the disease.Early anti-inflammatory treatment is mandatory in order to
rapidly achieve full disease control and to avoid occurrence
of irreversible changes in the airways. Careful attention
should be directed to achieve full anti-inflammatory
control, before stabilizing treatment is considered with
leukotriene antagonist, long-acting 2-agonist therapy or
theophylline.
On the other hand, it is likewise important to avoid
unnecessary long treatment with high dose corticosteroid.
It is necessary to continuously re-evaluate the actual
treatment in order to reach the lowest eective dose that
can control the disease. If the disease, after 1 year of
treatment, is dicult to control on a daily inhaled steroid
dose equivalent to more than 500 g beclomethasone
diproprionate daily, combination therapy with other anti-
inflammatory regimes such as chromones or leukotriene
antagonist should be considered. Before doing so, it is
important to rule out other possible causes of insucient
treatment response, such as improper compliance and
strong environmental trigger factors. If the disease is
dicult to control despite increased anti-inflammatory
treatment, addition of long acting 2-agonist or theophyl-
line is recommended.
Acute severe asthma
ACUTE SEVERE ASTHMA IN CHILDREN
AND ADULTS
Assessment of clinical severity should be based upon
clinical signs as breathlessness, respiratory rate, heart
frequency and mental status. As objective laboratory
measurements PEF and blood-gas analyses are used (see
Table 6).
A short and concise clinical history should be obtained.
This includes usual daily medication intake and medication
taken during the last 24 h. Known allergy, smoking history
and concomitant diseases are important to register. A
possible cause of the actual episode needs to be identified. It
is extremely important to rule out concomitant factors that
could endanger the outcome and initial handling of the
patient, such as pneumothorax, pneumonia, cardiac in-
suciency etc.
The patient is often frightened and agitated and it is of
utmost importance to secure a calm and confident atmo-
sphere around the treatment. Oxygen should be given
immediately and 2-agonist combined with ipratropium
bromide should be given by nebulizer driven by oxygen.
Steroids should always be given early in the course. In
most situations orally delivered prednisolone is sucient.
However, in very severe asthma, the first dose is preferably
given by injection, in order to secure delivery. A steroid
with low mineral corticosteroid eect should be used.
Repeated blood gas analyses is important early in the
course. Special attention should be given to a tendency to
respiratory acidosis, which in contrast to the COPD patient
may have a very rapid onset and development. Usually, a
slight respiratory acidosis is rapidly corrected as soon as the
ventilation improves. In rare circumstances, metabolic
TABLE 6. Severity of asthma exacerbations*
Mild Moderate Severe Respiratory
arrest imminent
Breathless Walking Talking
Infant-softer
and shorter
cry; diculty
feeding
At rest
Infant-stops
feeding
Can lie down Prefers sitting Hunched forward
Talks in Sentences Phrases Words
Alertness May be agitated Usually agitated Usually agitated Drowsy or
confused
Respiratory rate Increased Increased Often >30min71
Guide to rates of breathing associated with respiratory distress in awake children:
Age Normal rate
52 months 560/min
2–12 months 550/min
1–5 years 540/min
6–8 years 530 min
Accessory muscles
and suprasternal
retractions
Usually not Usually Usually Paradoxical
thoraco-
abdominal
movement
Wheeze Moderate, often only
end expiratory
Loud Usually loud Absence of
wheeze
Pulse/min 5100 100–120 4120 Bradycardia
Guide to limits of normal pulse rate in children:
Normal rate
Infants 2–12 months 5160/min
Pre-school 1–2 years 5120/min
School age 2–8 years 5110 min
Pulsus paradoxus Absent
5 10 mm Hg
May be present
10–25 mm Hg
Often present
4 25 mm Hg (adult)
20–40 mm Hg (child)
Absence suggests
respiratory muscle
fatigue
PEF after initial
bronchodilator
% predicted or
% personal best
Over 80% Approx. 60-80% 560% predicted
or personal best
(5 100 L/min adults)
or response
lasts 5 2 hrs
PaO2 (on air)
and/or
PaCO2
Normal
Test not usually
necessary
5 45 mm Hg
(6.0 kPa)
>60 mm Hg
(8.0 kPa)
5 45 mm Hg
(6.0 kPa)
5 60 mm Hg
(8.0 kPa)
Possible cyanosis
4 45 mm Hg
(6.0 kPa)
Possible respiratory failure
(see text)
SaO2 % (on air) 4 95% 91–95% 5 90%
Hypercapnia (hypoventilation) develops more readily in young
children than in adults and adolescents.
*The presence of several parameters, but not necessarily all, indicate the general classification of the exacerbation
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reasons for metabolic correction is to improve renal
haemodynamics and to restore -receptor function.
Very severe cases should always be monitored closely in
units prepared to assist ventilation mechanically whenever
needed.
The following signs should immediately result in
transferral to intensive observation:
1. impairment of speech;
2. impairment of mental alertness;
3. silent chest;
4. PaO2 58 kPa at admission;
5. hypercapnia PaCO2 46 kPa;
6. progression of disease severity.
The combination of the initial hyperventilation with
administration of 2-agonist may lead to significant
depletion of potassium in blood. However, the intracellular
potassium concentration is usually within the normal range,
and therefore this extra cellular depletion needs no
correction. However, special attention should be directed
to those patients who has been on long-term regular
treatment with loop diuretics. These patients may from the
start have depletion of intracellular as well as extracellular
potassium, and may have simultaneous depletion of
magnesium. In these cases, it may be advisable to correct
both potassium and magnesium levels.
In addition, steroids with marked mineral corticosteroid
eect can further contribute to the electrolyte disturbances
and should therefore be avoided.
In most circumstances, it is possible to manage the
patient with frequent high dose bronchodilator inhalation.
Systemic 2-agonist administration may be considered in
those with severe obstruction.
Theophylline is seldom necessary and usually gives no
additional eects when sucient 2-agonist and anti-
cholinergic treatment is given. Theophylline also has the
disadvantage of a narrow therapeutic window. From
clinical experience we know that a limited number of
patients benefit from the addition of theophylline. There-
fore theophylline should be given on an individual basis,
but cannot be generally recommended.
Sedatives, including anti-histamines with sedative ac-
tions, should be avoided and only given when the
possibility of immediate ventilator support is at hand.
Physiotherapy has no place in the initial management
plan.
CLASSIFICATION OF SEVERITY IN
CHILDREN
Clinical assessment
Registration of clinical observations is important, from the
initial evaluation to later examinations, in order to follow
the eect of treatment and progression of the illness.
Important clinical observations include respiratory rate and
pattern; heart rate, respiratory chest recessions, ausculta-
tory sounds, skin colour and, in children, the generalcondition and spontaneous activity. The respiratory rate
may vary, especially in early infancy. As a general rule the
respiratory rate should be below 40 per min during the first
year of life and in older children below 20 per min. The
respiratory pattern is usually changed during acute asthma
to be marked by a prolonged expiratory phase. The heart
rate is often high due to increased ventilatory work load
and the child’s anxiety. In spite of the positive chronotropic
eect of many asthma drugs, the heart rate often decreases
when the asthma attack is treated and the dyspnoea
recedes. The respiratory chest recessions during acute
asthma (jugular, intercostal and subcostal) is a good
measure of severity. By lung auscultation, presence of
prolonged expiratory phase, diminution of the respiratory
sounds over parts of or over the entire lung, or sounds such
as rhonchi and rales, should be observed. Diminished
respiratory sounds in the absence of extraneous respiratory
sounds such as rhonchi and rales may signify very severe
bronchopulmonary obstruction due to low airflow, and
should not be misinterpreted as a sign of improvement.
Rhonchi may become audible after the use of a broncho-
dilating drug. A clinical classification, developed by Kjell
Aas, of the bronchopulmonary obstruction during acute
asthma, based mainly upon lung auscultation, is given in
Table 7 (121).
LABORATORY AND TECHNICAL
ASSESSMENT OF ACUTE ASTHMA
Blood gases, pH and base excess are used routinely in
emergency rooms and hospital wards. PCO2 may be low
early during the acute exacerbation (hyperventilation) with
a normal PO2 in arterial or arterialized blood samples.
Increasing PCO2 towards or beyond the normal level
(54 kPa) may imply an increasing obstruction. In
respiratory failure PO2 decreases while PCO2 increases.
With PCO2 levels above 8 kPa in a patient without other
chronic respiratory disorders, ventilator treatment should
be considered.
Arterial oxygen saturation (SaO2) measured by pulse
oximetry is a useful and simple way of observing the acutely
ill asthmatic (122). SaO2 levels below 91% are regarded as
representing a severe condition in small children and
infants, levels of 91–93% indicate moderate asthma and
levels above 94% mild acute asthma. Whilst SaO2 has been
shown to be eective in surveillance, it is not suciently
sensitive to be used as a single criterion for admission to
hospital (123,124). Monitoring of transcutaneous arterial
blood gases is valuable in small children and infants with
acute asthma to detect deterioration (125) and to monitor
the eect of treatment (126).
Measurement of lung function is of value in the
assessment of acute asthma (PEFR, FEV1) (124). In severe
asthma forced expiratory manoeuvres may aggravate the
dyspnoea. Furthermore, these techniques are not suitable in
pre-school children.
Registration of tidal breathing pattern, by tidal flow–
time curves and tidal flow–volume curves in adults (127)
TABLE 7. Clinical assessment of bronchopulmonary obstruction during acute asthma in children
Score Description
P0 Normal; no signs of bronchopulmonary obstruction.
P1 No dyspnoea. Slightly faint respiratory sounds.
P2 No dyspnoea. Moderate rhonchi. Slightly prolonged expiration. The expiration may be audible.
P3 No dyspnoea at rest. Abundant rhonchi. Slight use of auxiliary respiratory muscles. Low grade jugular recessions
may be present.
P4 Slight dyspnoea at rest. Abundant rhonchi. Obvious use of auxiliary respiratory muscles. Jugular and intercostal
chest recessions. No cyanosis.
P5 Severe dyspnoea at rest. Abundant rhonchi. Wheezy expiration audible without stethoscope. Jugular, intercostal
and subcostal chest recessions. Slight cyanosis may be present.
P6 Alarming obstruction, often both inspiratory and expiratory. Faint respiratory sounds. Chest recessions. Use of
auxiliary respiratory muscles and high respiratory rate. Cyanosis may be present but not mandatory.
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tool in monitoring bronchopulmonary obstruction
(130,131).
ACUTE SEVERE ASTHMA IN CHILDREN
Treatment in the home
All children with the diagnosis of asthma need individua-
lized written instructions for treatment during acute
exacerbations. It is important to ascertain that the parents
(or the patient in case of school children and adolescents)
understand the instructions. It is usual to recommend that
the doctor/hospital should be contacted if the treatment
according to written instructions is without eect, if the
medication has a shorter duration than 3 h, if the child is
getting fatigued, or the dyspnoea lasts more than 3 days. A
practical guideline for the practitioner is that if an adequate
dose of inhaled nebulized 2-agonist is insucient, the
patient should be admitted to hospital.
During acute asthma, the eect of oral drugs is uncertain.
Inhaled 2-agonists, salbutamol or terbutaline (dosage, see
Table 7) may be given every third hour at home. If more
frequent inhalations are needed, the patient ought to be
admitted to hospital. In case of severe dyspnoea, the
administration of systemic steroids should be considered
before transportation to hospital, either orally (predniso-
lone or betamethasone) or as an intravenous injection
(hydrocortisone acetate).
Treatment of acute asthma in hospital
A plan for the management strategy of acute childhood
asthma in hospital is outlined. The management strategy
(Table 8) is based upon the classification of the acutely ill
asthmatic child according to the criteria given in Table 7.
The dosage of drugs is shown in Table 9.Ventilator treatment
Ventilator support may be required, based upon clinical
assessment. Is the patient fatigued? PCO258 kPa or PCO2
>7 kPa may necessitate ventilator support.
Laboratory examinations during acute asthma:
The following samples are taken when anticipated to have
consequences for treatment: Leukocytes, CRP, serum
theophylline levels, blood-gases and chest X-ray (important
in case of suspected pneumothorax); Surveillance: SaO2,
transcutaneous PO2, PCO2, electrocardiogram, blood-
pressure monitoring and electrolytes (2-agonist may
contribute to hypokalemia).
Special considerations
PREGNANCY
The severity of asthma during the period of pregnancy is
dicult to predict in individual cases. Approximately a
third of patients will improve, a third will be unchanged
and a third will get worse. Patient compliance is a major
target for therapeutic intervention. It is important to
inform the pregnant mother properly. Generally the disease
itself is a larger threat for the foetus health than any part of
the treatment (132,133,134). Inhaled corticosteroids
with inhaled 2-agonist therapy should be the cornerstone
of therapy. Oral theophylline may also be used and neither
of these drugs have been shown to increase the risk of
foetal malformations. Acute exacerbations should be
treated quickly in order to decrease the risk of foetal
asphyxia. Nebulized 2-agonist therapy and anticholiner-
gics, oxygen and systemic steroids should be used when
needed.
TABLE 8. Treatment of acute asthma
Asthma classification Management strategy
P1-P3: Mild You have ample time to investigate the case history and perform a thorough
clinical examination of the child. Give inhaled 2-agonists. Then wait for
10 min and give another dose of nebulized salbutamol or terbutaline if needed.
If necessary, take required samples for laboratory investigation.
If the treatment has a satisfactory eect (P0-P1 after treatment): the
patient may be discharged from hospital with home medication up to
every third hour. The parents are instructed to contact the hospital if the
condition aggravates.
P4-P6: Moderate to severe Do a rapid medical history and clinical investigation. Observe: pneumonia;
atelectasis, pneumothorax. Commence inhalation therapy while preparing
and setting up an intravenous cannula. Inhalation therapy is given as nebulized
2-agonists. Give oxygen therapy by face mask if needed.
If the response to inhalation therapy is non-satisfactory administer systemic
steroid treatment, repeat 2-agonist inhalation and consider nebulized
adrenaline or nebulized racemic adrenaline. Especially in infants and young
children nebulized adrenaline or racemic adrenaline can be useful.
Theophylline can be considered. If the child improves, continue surveillance.
If the child still has considerable dyspnoea, set up intravenous infusion
of fluids.
If the initial therapy does not improve the patient’s condition: prepare
transfer to an intensive care unit as soon as the patient is stabilized
clinically (heart condition and respiration).
320 R. DAHL AND L. BJERMERStarting specific allergen vaccination during pregnancy is
not recommended. However, if the treatment has been
initiated and titrated before the pregnancy occurred, it is
generally safe to continue (135), but the maintenance dose
should be modified.
PETS
Hypersensitivity to cat and/or dog allergens is commonly
found in individuals with allergic asthma (136,137). It is
often dicult to convince the patients to get rid of their
animals, even in a situation with evident clinical hypersen-
sitivity. It is even more dicult to recommend removal of
the pet in a situation where allergy is not yet present but
highly suspected in the future. Most atopic individuals with
animal allergy develop their hypersensitivity within the first
12 months. However, it may also appear at a later stage
after 2–6 years (138). A risk factor for development of pet
allergy in infants is atopic disposition, especially on the
maternal side (139). Increase of cord blood IgE may
identify individuals at greater risk (140). A large exposure
to a wide variety of known allergens in early infancy may
predispose to allergy later in life (141). Other important risk
factors are passive smoking increasing the risk of overall
sensitisation (142,143,16). Pet allergens are commonly
found in significant concentrations in most public places
and in homes without pets (144). Thus it is virtually
impossible to avoid pet allergen exposure. Today, there are
no data indicating that avoidance of pets in the homeprovides protection from being sensitized to pet allergen.
On the contrary, some studies indicate that early and
regular exposure to pets and farm animals protects against
sensitization (59,60).
EXERCISE-INDUCED ASTHMA
Exercise-induced asthma is a clinical manifestation of
bronchial hyper-responsiveness. Liability to experience
wheezing and obstruction in association with exercise varies
from one patient to another and also in the same patient
according to asthma severity. Consequently treatment with
anti-inflammatory medications should always be consid-
ered. Traditionally patients have been advised to inhale
short-acting 2-agonists or cromoglycate just before ex-
ercise, and a combination of the drugs has an additive
eect. Leukotriene antagonist treatment may serve as an
alternative. Pre-treatment with short-acting 2-agonist
before exercise is dicult to achieve in children. Therefore,
especially in active children, drugs with longer protective
action, i.e. covering the whole day, are recommended. The
combination of inhaled corticosteroids with a long-acting
2-agonist, or a leukotriene antagonist should be consi-
dered.
PHYSICAL ACTIVITY
Although physical exercise may trigger asthma attacks,
regular physical training, through improved fitness, may
TABLE 9. Treatment of acute severe asthma in children
Drug Dosage
Racemic adrenaline nebulizing solution 20-25 mg/ml 5 1/2 years old: 2–2.5mg (0.1ml) in 5 ml NaCl
(isotonic)
4 1/2 years old: 4–4.5mg (0.2ml) in 5 ml
NaCl (isotonic)
Salbutamol nebulizing solution 5 mg ml71 0.5–1.5 mg (0.1–0.3ml) / 10 kg body
weight in 5 ml NaCl (isotonic)
Ipratropium bromide nebulizing solution 0.25 mg ml71 0.05 mg (0.2 ml = 4 drops) in 2–5 ml NaCl (isotonic).
May be combined with salbutamol inhalation
Theophyllamine for intravenous use Saturating dose should be infused over 15 min:
6 mg/kg body weight, maximum 300 mg (in case of
regular theophylline use, half of the ordinary dose
should be given if the patient uses theophylline
regularly or has received theophylline during the last 6–8 h.
Maintenance dose:5 8 years: 0.9 mg kg71 body weight
per hour
4 8 years: 0.5–0.7 mg kg71 per hour
To be given in glucose 50 mg ml71 with added Na+2
mg kg71 body weight over 24 h, and K+ 1 mg kg71
body weight over 24 h.
Hydrocortisone (Solu-Cortef) or [Methylpredisolone
(Solu-Medrol)] intravenously
Initial dose: 100 mg [20mg]
20mg Solu-Medrol&100mg Solu-Cortef after that: 5 20 kg: 50 mg 6 4 (10mg 6 4)
4 20 kg: 100 mg 6 4 (20mg 6 4)
Terbutaline 0.5mg ml71 for intravenous infusion 5–10 mg kg71 and hour
Mixture of 5 mg (10 ml) terbutaline in 1000 ml
isotonic infusion solution
(1 ml = 5 mg, 10 drops=2.5 mg).
Adrenaline subcutaneously 1 mg ml71 0.01 ml kg71 (=0.1 ml per 10 kg) as a single dose
Prednisolone tablets 1–2 mg kg71 body weight per day in 4 days
NORDIC CONCENSUS REPORT ON ASTHMA MANAGEMENT 321increase the ability for physical performance (145,146,147).
Asthmatics should be encouraged to take part in physical
activity and exercise should be included in rehabilitation
programmes for asthmatic individuals. Proper pre-treat-
ment with 2-agonists and/or cromoglycate together with a
sucient warming-up reduce exercise-induced obstruction
(148). Often pre-treatment with a 2-agonist does not
suciently prevent exercise induced obstruction. It is then
advisable to add anti-inflammatory treatment, preferably a
low to medium dose of inhaled corticosteroids.
Exercise induced asthma is the most common feature
seen in children with asthma and should primarily be
regarded as an indicator of insucient asthma control. It is
dicult to instruct a child to take 2-agonist prophylacti-
cally before exercise. They often forget and sometimes do
not want to expose themselves by taking medication in
front of their class mates. In children, therefore, long-term
protection throughout the day is desirable. A combination
of a low-medium dose of inhaled corticosteroid and long-acting 2-agonist or leukotriene antagonist is recom-
mended.
GASTROESOPHAGEAL REFLUX
The incidence of gastroesophageal reflux (GER) and
oesophagitis is increased in asthmatics (149,150). The use
of xanthines may enhance the reflux by relaxation of the
lower oesophageal sphincter. Whether GER may trigger
asthma exacerbation and especially night asthma symptoms
is still debated. Simultaneous oesophagus pH and lung
function measurement, preferably continuously, help estab-
lish the diagnosis (151). Oral 2-agonists and xanthines
should be avoided. Patients should avoid eating between
meals and especially before bed time. Spicy food, coee and
alcohol should also be avoided. Present oesophagitis should
be treated with a proton-pump blocker. Surgery should be
considered in more severe cases.
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Viral infections are common triggers of asthma exacerba-
tion (152). However, viral infections may also contribute to
the development of asthma (153). Asthma in later life has
been associated with hospitalization due to RSV bronch-
iolitis in early childhood (154,155). Experimental studies
have also shown that viral infections may cause inflamma-
tory changes similar to those seen in asthma (154,156).
Careful prospective studies are needed to evaluate whether
early intervention is able to prevent the development of
asthma. Nevertheless data strongly support viral infections
as an important aetiological factor in some asthmatic
subjects. The definite value of early anti-inflammatory
intervention has not yet been proved. However, we suggest
that, especially for those infants and small children with
atopic disposition, in occurrences of viral induced bronch-
iolitis early treatment with anti-inflammatory medication,
i.e. inhaled steroids, should be given. Careful follow-up
during the following years is strongly recommended.
PSYCHOLOGICAL ASPECTS
To achieve optimal disease control it is important to secure
full patient compliance (157). The patient should early be
involved as a ‘partner’ in the treatment program. Full
insight into the disease mechanism and the formation of an
individual ‘self-management’ plan are corner stones in
modern asthma therapy (158). Information should be given
gradually, allowing the patient to digest the information
properly. Some information may be given in a group, i.e. as
an ‘asthma school’. However, most patients will also need
individual education. A trained nurse and/or physiothera-
pist is often essential partners in the process.
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